ClinicalTrials.gg
CompletedNCT02454972Updated Mar 2, 2023Results posted

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

A Phase 2 interventional study of lurbinectedin (PM01183) in Advanced Solid Tumors, sponsored by PharmaMar. Completed at 40 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by PharmaMar · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
345
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors

Read the detailed description

Patients with relapsed small cell lung cancer (SCLC), head and neck carcinoma (H\&N), neuroendocrine tumors (NETs), biliary tract carcinoma, endometrial carcinoma, BRCA 1/2-associated metastatic breast carcinoma, carcinoma of unknown primary site, germ cell tumors (GCTs), and Ewing's family of tumors (EFTs) will be enrolled in nine different cohorts. Up to 25 evaluable patients are planned to be enrolled in each cohort (50 in the endometrial carcinoma and 100 in the SCLC cohort).

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Voluntary signed (IC)
  • proven diagnosis of any of the following :

    • Small cell lung cancer (SCLC).
    • Head and neck carcinoma (H\&N). Salivary glands tumors are excluded.
    • Neuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.
    • Biliary tract carcinoma.
    • Endometrial carcinoma.
    • BRCA 1/2- associated breast carcinoma
    • Carcinoma of unknown primary site.
    • Germ cell tumor (GCTs), excluding immature teratoma, or teratoma with malignant transformation.
    • Ewing's family of tumors (EFTs)
  • Prior treatment. Patients must have received:

    • SCLC, endometrial carcinoma: one prior chemotherapy-containing line.
    • H\&N, NETs, biliary tract, CUP: one or two prior chemotherapy-containing lines
    • GCTs: no limit of prior therapy
    • EFTs: no more than two prior chemotherapy-containing lines in the metastatic/recurrent setting.
    • BRCA 1/2-associated metastatic breast carcinoma: at least one but no more than three prior chemotherapy-containing lines.
  • Performance status ≤ 2 [ (ECOG)]
  • Adequate major organ function
  • At least three weeks since the last chemotherapy
  • Women of must have pregnancy excluded by appropriate testing before study entry

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PM01183 or trabectedin
  • Prior or concurrent malignant disease unless in complete remission for more than five years
  • Known central nervous system (CNS) involvement
  • Relevant diseases or clinical situations which may increase the patient's risk
  • Pregnant or breastfeeding women and fertile patients (men and women) who are not using an effective method of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    lurbinectedin (PM01183)

    lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion

    Drug: lurbinectedin (PM01183)

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall Response Rate was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥30% decrease in the sum of the longest diameters of target lesions compared with baseline; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD

    Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)

  2. Response by Investigator Assessment

    When response is the primary endpoint, and thus all patients must have measurable disease to enter the trial, all patients included in the study must be accounted for in the report of the results, even if there are major protocol treatment deviations or if they are not evaluable. Each patient will be assigned one of the following: Complete Response: Disappearance of all target lesions; Partial Response: ≥30% decrease in the sum of the longest diameters of target lesions; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD; Inevaluable for response: specify reasons (for example: early death, malignant disease, toxicity; tumour assessments not repeated/incomplete; other). Normally, all eligible patients should be included in the denominator for the calculation of the response rate for phase II trials.

    Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)

Secondary outcomes

  1. Duration of Response

    Duration of Response by Investigator's Assessment, defined as the time between the date when the response criteria (PR or CR, whichever one is first reached) are fulfilled to the first date when disease progression (PD), recurrence or death is documented.

    Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)

  2. Clinical Benefit

    Clinical Benefit Rate was defined as Overall Response Rate or Stable Disease lasting over four months (SD ≥ 4 months)

    Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)

  3. Disease Control Rate

    Disease Control Rate was defined as Overall Response Rate or Stable Disease

    Time frame: From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6

  4. Progression Free Survival (PFS)

    Progression-free Survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest

    Time frame: From the date of first infusion to the date of progression disease, death (of any cause), or last tumor evaluation, up to an average of 5 years

  5. Progression-free Survival at 4 Months

    Progression-free Survival at 4, defined as the probability of being free from progression and death after the first infusion at 4 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest

    Time frame: At 4 months

  6. Progression-free Survival at 6 Months

    Progression-free Survival at 6, defined as the probability of being free from progression and death after the first infusion at 6 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest

    Time frame: At 6 months

  7. Overall Survival (OS)

    Overall survival defined as the period of time from the date of first infusion to the date of death or last contact in case of patients lost to follow-up or alive at the clinical cutoff established for the cohort.

    Time frame: From the date of first infusion to the date of death or last contact, up to an average of 5 years

  8. Overall Survival at 6 Months

    Overall Survival at 6 months defined as the probability of being alive after the first infusion at 6 months

    Time frame: At 6 months

  9. Overall Survival at 12 Months

    Overall Survival at 12 months defined as the probability of being alive after the first infusion at 12 months

    Time frame: At 12 months

07

Results

Posted Nov 22, 2021

Participant flow

The first patient registration was on 25 August 2015 and the first study treatment administration was on 25 August 2015. The last patient registration was on 30 November 2018 and the last study treatment administration was on 29 November 2019. The date of last follow-up (cutoff-date) was 18 September 2020.

Participant flow — Overall Study
MilestoneBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Started1919762924152132110
Treated1919732823152132105
Completed000000000
Not completed1919762924152132110
Withdrew: Progressive disease17165923161219270
Withdrew: Death0051000095
Withdrew: Physician decision012120010
Withdrew: Non treatment-related adverse event201001010
Withdrew: Treatment-related adverse events011020020
Withdrew: Patient moves to compassionate use000000200
Withdrew: Withdrawal by subject015232012
Withdrew: Multiple delay/holds on treatment000100000
Withdrew: Never treated003110005
Withdrew: Lost to follow-up000000002
Withdrew: Study termination000000006

Outcome measures

PrimaryOverall Response Rate (ORR)

Overall Response Rate was defined as the percentage of patients with a confirmed response, either CR or PR, according to the RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): ≥30% decrease in the sum of the longest diameters of target lesions compared with baseline; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD

Time frame:
From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Overall Response Rate (ORR)5.6 (0.1 to 27.3)0.0 (0.0 to 17.6)11.3 (5.0 to 21.0)14.3 (4.0 to 32.7)4.3 (0.1 to 21.9)0.0 (0.0 to 24.7)28.6 (11.3 to 55.2)6.5 (0.8 to 21.4)36.2 (27.0 to 46.1)
PrimaryResponse by Investigator Assessment

When response is the primary endpoint, and thus all patients must have measurable disease to enter the trial, all patients included in the study must be accounted for in the report of the results, even if there are major protocol treatment deviations or if they are not evaluable. Each patient will be assigned one of the following: Complete Response: Disappearance of all target lesions; Partial Response: ≥30% decrease in the sum of the longest diameters of target lesions; Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions; diameter recorded or the appearance of one or more new lesions; Stable Disease: Neither PR or PD; Inevaluable for response: specify reasons (for example: early death, malignant disease, toxicity; tumour assessments not repeated/incomplete; other). Normally, all eligible patients should be included in the denominator for the calculation of the response rate for phase II trials.

Time frame:
From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Reported as:
Count of participants · Participants
Response by Investigator Assessment
ParticipantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Complete Response002000000
Partial Response1064106238
Stable Disease51129128310934
Progressive disease11730912851828
Inevaluable for response114322025
SecondaryDuration of Response

Duration of Response by Investigator's Assessment, defined as the time between the date when the response criteria (PR or CR, whichever one is first reached) are fulfilled to the first date when disease progression (PD), recurrence or death is documented.

Time frame:
From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Reported as:
Median · months
Duration of Response
monthsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Duration of Response3.4 (NA to NA)—9.2 (3.4 to 18.0)4.2 (2.9 to 5.5)10.6 (NA to NA)—8.6 (2.9 to NA)4.7 (4.0 to 5.4)5.3 (4.1 to 6.2)
SecondaryClinical Benefit

Clinical Benefit Rate was defined as Overall Response Rate or Stable Disease lasting over four months (SD ≥ 4 months)

Time frame:
From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)
Reported as:
Number · percentage of participants
Clinical Benefit
percentage of participantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Clinical Benefit11.1 (1.4 to 34.7)36.8 (16.3 to 61.6)35.2 (24.2 to 47.5)39.3 (21.5 to 59.4)26.1 (10.2 to 48.4)15.4 (1.9 to 45.4)57.1 (34.0 to 78.2)29.0 (14.2 to 48.0)45.7 (36.0 to 55.7)
SecondaryDisease Control Rate

Disease Control Rate was defined as Overall Response Rate or Stable Disease

Time frame:
From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6
Reported as:
Number · percentage of paticipants
Disease Control Rate
percentage of paticipantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Disease Control Rate33.3 (13.3 to 59.0)57.9 (33.5 to 79.7)52.1 (39.9 to 64.1)57.1 (37.2 to 75.5)39.1 (19.7 to 61.5)23.1 (5.0 to 53.8)76.2 (52.8 to 91.8)35.5 (19.2 to 54.6)68.6 (58.8 to 77.3)
SecondaryProgression Free Survival (PFS)

Progression-free Survival (PFS), defined as the period of time from the date of first infusion to the date of PD, death (of any cause), or last tumor evaluation. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest

Time frame:
From the date of first infusion to the date of progression disease, death (of any cause), or last tumor evaluation, up to an average of 5 years
Reported as:
Median · months
Progression Free Survival (PFS)
monthsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Progression Free Survival (PFS)1.3 (1.1 to 2.5)2.7 (1.3 to 4.4)2.6 (1.4 to 4.0)2.7 (1.4 to 4.3)1.5 (0.9 to 8.9)1.3 (1.2 to 2.1)4.1 (2.3 to 6.5)1.4 (1.2 to 3.0)3.7 (2.6 to 4.3)
SecondaryProgression-free Survival at 4 Months

Progression-free Survival at 4, defined as the probability of being free from progression and death after the first infusion at 4 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest

Time frame:
At 4 months
Reported as:
Number · percentage of participants
Progression-free Survival at 4 Months
percentage of participantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Progression-free Survival at 4 Months13.7 (0.0 to 31.1)38.9 (16.4 to 61.4)39.7 (28.2 to 51.3)46.2 (27.0 to 65.3)30.7 (11.0 to 50.4)15.4 (0.0 to 35.0)57.1 (36.0 to 78.3)30.0 (13.6 to 46.4)46.5 (36.8 to 56.3)
SecondaryProgression-free Survival at 6 Months

Progression-free Survival at 6, defined as the probability of being free from progression and death after the first infusion at 6 months. Progressive disease: ≥20% increase in the sum of the longest diameter of target lesions compared with the smallest-sum longest

Time frame:
At 6 months
Reported as:
Number · percentage of participants
Progression-free Survival at 6 Months
percentage of participantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Progression-free Survival at 6 Months13.7 (0.0 to 31.1)22.2 (3.0 to 41.4)29.0 (18.2 to 39.8)23.1 (5.9 to 40.3)30.7 (11.0 to 50.4)7.7 (0.0 to 22.2)33.3 (13.2 to 53.5)16.7 (3.3 to 30.0)33.4 (24.1 to 42.6)
SecondaryOverall Survival (OS)

Overall survival defined as the period of time from the date of first infusion to the date of death or last contact in case of patients lost to follow-up or alive at the clinical cutoff established for the cohort.

Time frame:
From the date of first infusion to the date of death or last contact, up to an average of 5 years
Reported as:
Median · months
Overall Survival (OS)
monthsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Overall Survival (OS)7.3 (2.7 to 8.9)7.7 (3.8 to 18.8)9.3 (6.1 to 12.8)12.0 (8.5 to 18.5)9.2 (2.7 to 17.4)5.7 (2.1 to 12.1)16.1 (8.7 to NA)7.4 (3.4 to 16.2)8.1 (6.5 to 10.9)
SecondaryOverall Survival at 6 Months

Overall Survival at 6 months defined as the probability of being alive after the first infusion at 6 months

Time frame:
At 6 months
Reported as:
Number · percentage of participants
Overall Survival at 6 Months
percentage of participantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Overall Survival at 6 Months58.2 (34.5 to 82.0)55.6 (32.6 to 78.5)62.8 (51.2 to 74.4)88.2 (75.7 to 100.0)55.0 (32.8 to 77.1)38.5 (12.0 to 64.9)79.2 (61.0 to 97.4)52.1 (33.9 to 70.3)68.6 (59.5 to 77.6)
SecondaryOverall Survival at 12 Months

Overall Survival at 12 months defined as the probability of being alive after the first infusion at 12 months

Time frame:
At 12 months
Reported as:
Number · percentage of participants
Overall Survival at 12 Months
percentage of participantsBiliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer Cohort
Overall Survival at 12 Months21.8 (0.4 to 43.3)36.5 (13.1 to 59.8)45.8 (33.8 to 75.9)48.5 (27.8 to 69.2)34.4 (11.3 to 57.4)30.8 (5.7 to 55.9)58.1 (35.9 to 80.2)38.2 (20.5 to 55.9)34.8 (25.5 to 44.1)

Adverse events

Collected over From the date of first infusion to the date of death or last contact, up to an average of 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurbinectedin (PM01183)261/335 (77.9%)136/335 (40.6%)330/335 (98.5%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventLurbinectedin (PM01183)
Febrile neutropeniaBlood and lymphatic system disorders20/335
NeutropeniaBlood and lymphatic system disorders15/335
General physical health deteriorationGeneral disorders15/335
ThrombocytopeniaBlood and lymphatic system disorders12/335
Abdominal painGastrointestinal disorders11/335
AnaemiaBlood and lymphatic system disorders10/335
PneumoniaInfections and infestations8/335
DyspnoeaRespiratory, thoracic and mediastinal disorders8/335
VomitingGastrointestinal disorders7/335
HyponatraemiaMetabolism and nutrition disorders7/335
Most frequent other events
Showing 10 of 27
Most frequent other events
EventLurbinectedin (PM01183)
NauseaGastrointestinal disorders167/335
AstheniaGeneral disorders129/335
FatigueGeneral disorders122/335
ConstipationGastrointestinal disorders116/335
Decreased appetiteMetabolism and nutrition disorders102/335
NeutropeniaBlood and lymphatic system disorders89/335
DyspnoeaRespiratory, thoracic and mediastinal disorders77/335
VomitingGastrointestinal disorders76/335
DiarrhoeaGastrointestinal disorders62/335
AnaemiaBlood and lymphatic system disorders59/335

Baseline characteristics

Treated patients only

Age, Categorical
Age, Categorical(Participants)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
<=18 years0000000000
Between 18 and 65 years13103727209191968222
>=65 years693613621337113
Age, Continuous
Age, Continuous(years)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
Median61 (34 to 74)61 (27 to 78)64 (32 to 80)33 (18 to 74)36 (21 to 73)62 (39 to 81)45 (29 to 73)63 (23 to 77)60 (40 to 83)60 (18 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
Female1011731271211242189
Male98016161402063146
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
White131545211512182479242
Black of African American0051000017
Asian0012110016
American Indian or Alaska native0000000101
Not race available6422472372479
Region of Enrollment
Region of Enrollment(Participants)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
Sweden0000000101
Belgium22310002313
United States361716124261177
Italy0003100026
United Kingdom01900000313
France4217362352062
Switzerland00200010710
Germany0020000002
Spain10823549151859151
Eastern Cooperative Oncology Group performance status
Eastern Cooperative Oncology Group performance status(Participants)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
05832112518838127
114103516191022359188
201612011820
Weight
Weight(kg)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
Median72.2 (45.0 to 115.0)65.0 (50.1 to 108.2)70.0 (42.5 to 140.8)77.0 (51.0 to 127.7)78.5 (59.0 to 116.3)73.0 (49.0 to 107.0)65.5 (52.0 to 115.1)64.0 (47.0 to 121.0)71.0 (46.0 to 138.3)71.0 (42.5 to 140.8)
Height
Height(cm)Biliary Tract Carcinoma CohortCarcinoma of Unknown Primary Site CohortEndometrial Carcinoma CohortEwing's Family of Tumors CohortGerm Cell Tumors CohortHead and Neck Carcinoma CohortBRCA1/2-associated Metastatic Breast Carcinoma CohortNeuroendocrine Tumors CohortSmall Cell Lung Cancer CohortTotal
Median168 (148 to 187)164.5 (141 to 187)161 (143 to 180)173 (155 to 193)177 (157 to 190)170 (155 to 186)163.0 (147 to 177)169 (150 to 190)167 (150 to 183)165 (141 to 193)

15 further baseline measures are reported on the registry.

08

Study locations

40 sites
  • Sarcoma Oncology Research Center, LLC
    Santa Monica, California 90403, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Massachussets General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Centre
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Institute for Drug Development, Cancer Therapy & Research Center at University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Hôpital Cochin
    Paris, 75014, France
  • Institut Claudius Regaud
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Charité Universitätsmedizin Berlin - Campus Benjamin Franklin - Comprehensive Cancer Center
    Berlin, 12200, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Istituto Clinico Humanitas
    Rozzano, Milan 20089, Italy
  • Istituto Ortopedico Rizzoli
    Bologna, Italy
  • lstituto Europeo di Oncologia
    Milano, 20141, Italy
  • ASST Monza - Ospedale San Gerardo di Monza Struttura Complessa di Oncologia Medica
    Monza, 20090, Italy
  • AUSL Romagna - Ospedale Santa Maria delle Croci
    Ravenna, 48121, Italy
  • Complexo Hospitalario Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, Asturias 33011, Spain
  • Hopsital Universitario Donostia - Donostia Unibertsitate Ospitalea
    San Sebastián, Guipúzcoa 20014, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Complejo Hospitalario De Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Álvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
  • Hospital de Basurto
    Bilbao, Vizcaya 48013, Spain
  • Complexo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • Hospital Universitari Vall D' Hebron
    Barcelona, 08035, Spain
  • Complejo Hospitalario Regional Reina Sofía
    Cordoba, 14004, Spain
  • Hospital Universitario Virgen de las Nieves
    Granada, 18014, Spain
  • Hospital Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Complejo Hospitalario de Especialidades Virgen de la Victoria
    Malaga, 29010, Spain
  • Hospital Universitari i Polotècnic la Fe
    Valencia, 46026, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Skane University Hospital
    Lund, 22185, Sweden
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, Vaud 1011, Switzerland
  • Istituto Oncologico della Svizzera Italiana (IOSI)
    Bellinzona, 6500, Switzerland
  • UCL Cancer Institute
    London, WC1E 6DD, United Kingdom
09

References and documents

Publications

  • Boni V, Pistilli B, Brana I, Shapiro GI, Trigo J, Moreno V, Castellano D, Fernandez C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Anton A, Paredes A, Huidobro G, Subbiah V. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO Open. 2022 Oct;7(5):100571. doi: 10.1016/j.esmoop.2022.100571. Epub 2022 Aug 28. PubMed 36037567 ↗
  • Longo-Munoz F, Castellano D, Alexandre J, Chawla SP, Fernandez C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-Garcia E, Awada A, Santaballa A, Subbiah V. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 Sep;172:340-348. doi: 10.1016/j.ejca.2022.06.024. Epub 2022 Jul 10. PubMed 35830841 ↗
  • Subbiah V, Brana I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clin Cancer Res. 2022 Jul 1;28(13):2762-2770. doi: 10.1158/1078-0432.CCR-22-0696. PubMed 35486638 ↗
  • Fernandez-Teruel C, Fudio S, Lubomirov R. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. Cancer Chemother Pharmacol. 2022 May;89(5):585-594. doi: 10.1007/s00280-021-04366-3. Epub 2021 Nov 5. PubMed 34739582 ↗
  • Subbiah V, Paz-Ares L, Besse B, Moreno V, Peters S, Sala MA, Lopez-Vilarino JA, Fernandez C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Zaman K, Lopez R, Ponce S, Boni V, Arrondeau J, Delord JP, Martinez M, Wannesson L, Anton A, Valdivia J, Awada A, Kristeleit R, Olmedo ME, Rubio MJ, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D' Arcangelo M, Santoro A, Villalobos VM, Sands J, Trigo J. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020 Dec;150:90-96. doi: 10.1016/j.lungcan.2020.10.003. Epub 2020 Oct 10. PubMed 33096421 ↗
  • Trigo J, Subbiah V, Besse B, Moreno V, Lopez R, Sala MA, Peters S, Ponce S, Fernandez C, Alfaro V, Gomez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martinez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Erratum In: Lancet Oncol. 2020 Dec;21(12):e553. doi: 10.1016/S1470-2045(20)30676-8. PubMed 32224306 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Sep 2020, 60 months.

Results were first posted in Nov 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2015
First posted
May 27, 2015
StartActual
Aug 25, 2015
Primary completionActual
Sep 18, 2020
CompletionActual
Sep 18, 2020
Results first posted
Nov 22, 2021
Last update
Mar 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02454972
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
May 27, 2015
Start date
Aug 25, 2015
Primary completion
Sep 18, 2020
Completion
Sep 18, 2020
Results posted
Nov 22, 2021
Last update
Mar 2, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion